For a child diagnosed with neuroblastoma with bone marrow involvement, which is a favorable prognostic factor?

For a child diagnosed with neuroblastoma, non-amplification of the n-myc gene is considered a favorable prognostic factor. The n-myc gene is an oncogene that, when amplified, is associated with a higher risk of aggressive disease and poor outcomes. In neuroblastoma, the presence of n-myc amplification is linked to advanced disease stages and lower survival rates. Conversely, children with tumors that do not show this amplification tend to have a better prognosis, as their disease is often less aggressive.

Factors such as age and response to treatment also play significant roles in prognosis, with younger children typically having better outcomes, while older age (over 10 years) tends to be a poorer prognostic indicator. A poor response to treatment clearly indicates an adverse outcome. Thus, the presence of non-amplification of the n-myc gene stands out as a positive sign in the context of neuroblastoma with bone marrow involvement.